Compare Enveric Biosciences Inc (ENVB) vs iShares MSCI Singapore ETF (EWS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs iShares MSCI Singapore ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while iShares MSCI Singapore ETF trades at $31.6 (market cap $1.53B). The key difference: iShares MSCI Singapore ETF is far larger — about 228.7× Enveric Biosciences Inc's market cap, and iShares MSCI Singapore ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and iShares MSCI Singapore ETF for 45 Days on average.
| ENVB | EWS | |
|---|---|---|
Market Cap | $6.69M | $1.53B |
Volume | 41,141 | 1,666,115 |
Sector | Health | Broad Market / Factor |
52-Week High | $10.80 | $34.57 |
52-Week Low | $1.27 | $26.71 |
Typical Hold Time | 14 Days | 45 Days |
Enterprise Value | -$1.60M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
EWS, the iShares MSCI Singapore ETF, trades at $32.48, down 2.17% amid bearish technical signals. The ETF recently hit a 52-week high, driven by Singapore's economic strength and AI momentum, but faces selling pressure with key support at $32. Financial ratios are unavailable, limiting fundamental clarity.
Outlook remains mixed; Singapore's growth and institutional interest offer upside, but stretched valuations and technical weakness pose risks. Investors should weigh regional economic resilience against potential pullbacks in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →
